Posts With Tag Immunology

Explore AstraZeneca's Q3 2025 financial performance highlighting an 11% revenue growth, improved margins, and a strong pipeline. A must-read for investors!

AstraZeneca's Tezspire is now approved in the EU for chronic rhinosinusitis with nasal polyps, addressing unmet medical needs. Significant trial results highlight its efficacy.

AstraZeneca's report highlights Tezspire's EU approval for CRSwNP, showcasing significant trial results and market potential. A game-changer for 320M affected globally.

Explore AstraZeneca's latest Form 6-K report detailing promising Saphnelo trial results for SLE, highlighting innovative treatment options and future regulatory steps.

Explore Protagonist Therapeutics' Q4 2024 financial report showcasing $434.4M revenue, $275.2M net income, and a strong 'Buy' recommendation for investors seeking growth in biotech.

Dive into AbbVie Inc.'s 2024 financial performance with $56.33B in revenues, key product insights, and future outlook amid litigation risks. Explore our hold recommendation.

Discover Evaxion Biotech A/S's latest Form 6-K report detailing debt conversion strategies and compliance efforts. Stay informed on AI-Immunology™ advancements and investor relations.